ADC Therapeutics posts Q4 revenue $22.3M; net loss narrows; LOTIS-5 topline data expected Q2 2026

ADC Therapeutics SA

Q4 net product revenue $22.3M, full year $73.6M, up from $16.4M and $69.3M respectively in 2024.
Q4 net loss $6.4M ($0.04/share) vs $30.7M ($0.29/share) in 2024; adjusted net loss $13.5M.
Cash and cash equivalents $261.3M; expected cash runway at least into 2028.
LOTIS-5 Phase 3 topline data in 2L+ DLBCL expected Q2 2026; LOTIS-7 full data by year-end 2026.
Amendment to HealthCare Royalty financing reduces change-of-control payment to $150M through 2027; warrants for 9.8M shares at $3.81.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ADC Therapeutics SA reported financial results for the fourth quarter and year ended December 31, 2025.

Period: the fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 10, 2026, ADC Therapeutics SA (the "Company") issued a press release announcing the Company's financial results for the fourth quarter and year ended December 31, 2025.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ADC Therapeutics SA filing history →

Source: SEC EDGAR

accession 0001628280-26-016238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.